{"preliminary_commentary":{"by_channel":{"podcast":10,"x_thread":6,"youtube":2},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04620200\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["nivolumab","ipilimumab"],["nivolumab"]],"indication":"resectable advanced cutaneous squamous cell carcinoma","name":"MATISSE","nct_id":"NCT04620200","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=matisse-nct04620200. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"MATISSE","arms":[{"description":"2 courses of nivolumab 3 mg/kg in week 0 and 2 prior to standard of care","label":"ARM A","type":"EXPERIMENTAL"},{"description":"2 courses of nivolumab 3 mg/kg in week 0 and 2 plus 1 course of ipilimumab 1mg/kg in week 0 prior to standard of care","label":"ARM B","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2025-01-07","type":"ACTUAL"},"conditions":["Cutaneous Squamous Cell Carcinoma"],"enrollment":{"count":50,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Nivolumab","otherNames":["immunotherapy"],"type":"DRUG"},{"name":"Ipilimumab","otherNames":["immunotherapy"],"type":"DRUG"}],"last_update":"2025-08-11","lead_sponsor":"The Netherlands Cancer Institute","official_title":"Neo-adjuvant Nivolumab or Nivolumab With Ipilimumab in Advanced Cutaneous Squamous Cell Carcinoma Patients Prior to Standard of Care Surgery; the MATISSE Trial","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2025-01-07","type":"ACTUAL"},"primary_outcomes":[{"measure":"Histopathological response rate at standard of care","timeFrame":"At time of standard of care at week 4"}],"references":[{"citation":"Breukers SE, Traets JJH, van Dijk SW, Ostos MM, Fraterman I, Crommelin RD, van der Hulst H, Qiao X, Boere T, van de Poll-Franse LV, Retel V, van der Noort V, Vos JL, Toppenberg AGL, van der Heijden M, Missale F, Balm F, van den Brekel M, Dirven R, Karakullukcu MB, Karssemakers L, Klop WMC, Lohuis PJFM, Schreuder WH, Smeele LE, van der Velden LA, Plasmeijer E, Smit LA, de Boer JP, Navran A, Westerink B, de Koekkoek-Doll PK, Castelijns J, Wondergem M, Vogel WV, Kuijpers A, van Houdt WJ, Onderwater S, Maas-Bannink E, Cornelissen S, Broeks A, Tijink BM, Devriese LA, de Bree R, Blank CU, Schumacher TN, Thommen DS, Haanen JBAG, Zuur CL. Neoadjuvant ipilimumab and nivolumab in resectable cutaneous squamous cell carcinoma: a randomized phase 2 trial. Nat Med. 2025 Dec;31(12):4055-4064. doi: 10.1038/s41591-025-03943-w. Epub 2025 Oct 8.","pmid":"41062829","type":"DERIVED"}],"start_date":{"date":"2020-08-11","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Neo-adjuvant Nivolumab or Nivolumab With Ipilimumab in Advanced Cutaneous Squamous Cell Carcinoma Prior to Surgery","url":"https://clinicaltrials.gov/study/NCT04620200"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/matisse-nct04620200"}